1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This NOFO invites eligible United States small business concerns (SBCs) to submit STTR Phase I and Fast-Track grant applications.
The NHLBI will support Phase I and Fast-Track applications from early-career scientists and investigators with data science, artificial intelligence/machine learning, engineering, clinical care and other biomedical backgrounds who are new to the NIH SBIR/STTR programs. Applications submitted to this NOFO are not allowed to propose clinical trial(s).
Get alerted about grants like this
Save a search for “National Heart, Lung, and Blood Institute (NHLBI) / NIH” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93. 865 -- Child Health and Human Development Extramural Research 93. 879 -- Medical Library Assistance 93.
361 -- Nursing Research 93. 350 -- National Center for Advancing Translational Sciences 93. 233 -- National Center on Sleep Disorders Research 93.
213 -- Research and Training in Complementary and Integrative Health 93. 273 -- Alcohol Research Programs 93. 837 -- Cardiovascular Diseases Research 93.
839 -- Blood Diseases and Resources Research 93. 867 -- Vision Research 93. 121 -- Oral Diseases and Disorders Research 93.
113 -- Environmental Health 93. 172 -- Human Genome Research 93. 173 -- Research Related to Deafness and Communication Disorders 93.
838 -- Lung Diseases Research 93. 279 -- Drug Abuse and Addiction Research Programs 93. 840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93.
859 -- Biomedical Research and Research Training 93. 846 -- Arthritis, Musculoskeletal and Skin Diseases Research Last Updated: May 13, 2026 View version history on Grants.
gov Through this Notice of Funding Opportunity (NOFO), the National Institutes of Health (NIH) aims to facilitate the career development and transition of investigators new to entrepreneurship with an interest in small business by simultaneously supporting their entrepreneurial development and the conduct of research and development under their direction.
This NOFO supports small business concerns (SBCs) in employing and developing researchers as entrepreneurial Program Directors/Principal Investigators (PDs/PIs). In addition to augmenting scientific research staff and supporting research and development efforts at SBCs, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI.
Optimal PDs/PIs for this award are scientists and professionals with strong research, technology development, and/or healthcare delivery skills and experience, but limited entrepreneurial and independent research project leadership experience.
PDs/PIs are expected to grow their entrepreneurial skillset while working in a small business to develop promising technologies and products that align with NIH's mission to improve health and save lives. Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
File name Description Last updated PAR-24-133-Full-Announcement. html PAR-24-133 Full Announcement Text Apr 25, 2024 04:03 PM UTC Link to additional information https://grants. nih.
gov/grants/guide/pa-files/PAR-24-133. html Archived: November 18, 2025 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Income security and social services Your account requires additional identity verification.
According to the current listing, eligibility includes: United States small business concerns (SBCs). Confirm the full requirements in the official notice before applying.
The current listing shows not specified, but SBIR Phase I can be up to $305K and Phase II up to $1.25M+. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) is funded by National Heart, Lung, and Blood Institute (NHLBI) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Growing Data-science Research in Africa to Stimulate Progress (GRASP) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. The GRASP program supports data-science research in Africa to stimulate progress. While the provided information is an award notice, it indicates an active program with a performance end date in July 2026, suggesting ongoing or upcoming related opportunities. The NIH supports a diverse mix of research projects in Sub-Saharan Africa.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This program supports small businesses in accelerating the commercialization of technologies for heart, lung, blood, and sleep disorders. It is a Phase IIB Bridge Award, indicating it targets projects that have already demonstrated success in earlier SBIR/STTR phases.
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This Notice of Funding Opportunity invites small businesses to submit SBIR grant applications to support later stage research and development (Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and address rare diseases or young pediatr…
NIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleNIH committed $402 million across 601 multiyear-funded grants in the first eight months of FY 2026 — more than four times the pace of two years ago. The mechanism front-loads obligations into a single fiscal year, leaving less budget for new project starts and squeezing FY 2026 success rates. What researchers and institutions should be doing now.
Read articlePAR-26-042 funds NLM-priority clinical informatics R01 grants up to $250,000 in direct costs per year through March 6, 2029, with standard NIH cycles on October 5, February 5, and June 5. The notice explicitly defines non-responsive applications: incremental tool improvements, projects primarily focused on social determinants of health, and projects primarily focused on ethical/legal/social issues. With NIH SBIR/STTR just reopened and the OMB Uniform Grants Regulation rewrite reshaping discretionary awards, the NLM clinical informatics line is one of the few stable, well-defined biomedical funding streams left at the agency. Here is how to read it.
Read article